Boehringer gets respiratory boost with batch of Spiolto nods in EU

Carly Helfand When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged ...

Kiadis banks $36M in a Euro IPO to fund its stem cell R&D

Damian Garde Dutch drug developer Kiadis Pharma pulled in €32.7 million ($ 36.3 million) in a European IPO, raising cash to develop a pair of stem cell treatments. FierceBiotech ...

With vet drugs pumping, it’s no wonder that pharma’s eyeing M&A

Carly Helfand What's with all the M&A rumors floating around in the animal health world? Just look at Zoetis' Apoquel and it's clear why Big Pharma names are keen ...

Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories ...

Valeant makes offer for Zoetis, sources tell WSJ

Eric Palmer Rapidly expanding Valeant has approached Zoetis about a buyout, sources told the Wall Street Journal. Rumors of a possible deal, which have been bouncing back and forth ...

Chris Viehbacher explains: “If I had $2 billion to invest…”

John Carroll Not long ago, Viehbacher had a chance to sit down with Ernesto Bertarelli–who made a fortune on the sale of Serono–to pursue a conversation that many people ...

Merck launches Sivextro in U.K.

Eric Palmer Merck is launching Sivextro, the newly approved antibiotic it picked up in its $ 9.5 billion buyout of Cubist, in the U.K. Pharmafile reports it is the first oral treatment ...

Genentech’s PD-L1 breakthrough star ‘atezo’ positioned to vault ahead on cancer

John Carroll Behind the headlines here at ASCO, you'll find one of the biggest players in immuno-oncology quietly positioning itself to grab a leading role in the fast-emerging ...

Biotech’s boom spells a spike in R&D down payments

Damian Garde The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset ...

GSK closing Pittsburgh office, putting 275 jobs at risk

Eric Palmer The big asset swap between GlaxoSmithKline and Novartis may have given each just what it wanted, but the deal continues to play out poorly for workers, with GSK planning ...

Vertex’s Kalydeco combo could run payers $10M-plus per life, PBM figures

Carly Helfand Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex will stir ...

Flexus founders regroup after $1.25B Bristol-Myers deal

Damian Garde Flexus Biosciences turned heads around the industry when Bristol-Myers Squibb signed a $ 1.25 billion deal to buy the fledgling biotech in February, but the company's ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS